Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy

被引:15
作者
Sewell, Justin L. [1 ]
Stick, Kristine M. [2 ]
Monto, Alexander [1 ,2 ]
机构
[1] Univ Calif San Francisco, Gastroenterol Sect, San Francisco, CA 94143 USA
[2] Vet Affairs Med Ctr, Gastroenterol Sect, San Francisco, CA 94121 USA
关键词
hepatitis C; hepatocellular carcinoma; interferon; ribavirin; screening; sustained virologic response; INTERFERON THERAPY; DOWN-REGULATION; RISK; HEPATOCARCINOGENESIS; PROGRESSION; FIBROSIS; STAGE;
D O I
10.1097/MEG.0b013e32831101b7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Among hepatitis C patients, lack of cirrhosis and sustained virologic response (SVR) reduce the risk of hepatocellular carcinoma (HCC). Japanese studies document multiple cases of HCC among these patients, but only one case has been reported outside of Asia. We identified five patients with hepatitis C in our university-based hepatology practice who developed HCC despite SVR and lack of cirrhosis on their pretreatment liver biopsy. At the time of HCC diagnosis, two remained noncirrhotic, one had clearly progressed to cirrhosis, and two lacked repeat histology. We present these patients in a case series format and discuss several important implications of their cases. Physicians often base screening and treatment decisions on an initial liver biopsy performed years earlier. As fibrosis may advance, and because SVR and lack of cirrhosis do not fully protect against HCC, future study should further evaluate the risk of HCC among hepatitis C patients after sustained virologic response. Eur J Gastroenterol Hepatol 21:225-229 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
引用
收藏
页码:225 / 229
页数:5
相关论文
共 20 条
[1]   CHRONIC HEPATITIS - AN UPDATE ON TERMINOLOGY AND REPORTING [J].
BATTS, KP ;
LUDWIG, J .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1995, 19 (12) :1409-1417
[2]   A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma [J].
Bekaii-Saab, Tanios ;
Williams, Nita ;
Plass, Christoph ;
Calero, Miguel Villalona ;
Eng, Charis .
BMC CANCER, 2006, 6 (1)
[3]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[4]   Interferon and prevention of hepatocellular carcinoma in viral cirrhosis:: an evidence-based approach [J].
Cammà, C ;
Giunta, M ;
Andreone, P ;
Craxì, A .
JOURNAL OF HEPATOLOGY, 2001, 34 (04) :593-602
[5]   Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment [J].
Chavalitdhamrong, Disaya ;
Tanwandee, Tawesak .
WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (34) :5532-5535
[6]   Hepatocellular carcinoma and hepatitis C in the United States [J].
El-Serag, HB .
HEPATOLOGY, 2002, 36 (05) :S74-S83
[7]  
Enokimura N, 2003, ANTICANCER RES, V23, P593
[8]   Occult viral hepatitis and noncirrhotic hepatocellular carcinoma [J].
Gordon, SC .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (08) :1754-1757
[9]   Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy [J].
Iwasaki, Y ;
Takaguchi, K ;
Ikeda, H ;
Makino, Y ;
Araki, Y ;
Ando, M ;
Kobashi, H ;
Kobatake, T ;
Tanaka, R ;
Tomita, M ;
Senoh, T ;
Kawaguchi, M ;
Shimoe, T ;
Manabe, K ;
Kita, K ;
Shimamura, J ;
Sakaguchi, K ;
Shiratori, Y .
LIVER INTERNATIONAL, 2004, 24 (06) :603-610
[10]   Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation [J].
Kremer-Tal, Sigal ;
Narla, Goutham ;
Chen, Yingbei ;
Hod, Eldad ;
DiFeo, Analisa ;
Yea, Steven ;
Lee, Ju-Seog ;
Schwartz, Myron ;
Thung, Swan N. ;
Fiel, Isabel M. ;
Banck, Michaela ;
Zimran, Eran ;
Thorgeirsson, Snorri S. ;
Mazzaferro, Vincenzo ;
Bruix, Jordi ;
Martignetti, John A. ;
Llovet, Josep M. ;
Friedman, Scott L. .
JOURNAL OF HEPATOLOGY, 2007, 46 (04) :645-654